Linsitinib (OSI-906)

目录号：S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。

规格 价格 库存 购买数量  
RMB 1550.54 现货
RMB 1393.48 现货
RMB 2226.24 现货
RMB 5899.91 现货
有超大折扣
大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck该产品发表文献33篇：

客户使用该产品的6个实验数据：

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

产品安全说明书

IGF-1R抑制剂选择性比较

生物活性

产品描述 Linsitinib (OSI-906)是一种选择性IGF-1R抑制剂，在无细胞试验中IC50为35 nM；对InsR抑制作用适中，IC50为75 nM，对Abl，ALK，BTK，EGFR， FGFR1/2，PKA等没有抑制活性。Phase 3。
靶点
IGF-1R [1]
(Cell-free assay)		 Insulin Receptor [1]
(Cell-free assay)		 IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外研究

OSI-906 抑制IGF-IR自磷酸化和下游信号蛋白AKT, ERK1/2和S6激酶的激活，IC50为0.028到 0.13 μM。OSI-906通过与C-螺旋相互作用而使靶点蛋白形成中间结构形态。OSI-906作用于肝脏微粒体，具有良好的代谢稳定性。OSI-906浓度为1μM时，完全抑制IR 和IGF-IR磷酸化。OSI-906抑制一些肿瘤细胞系增殖，包括非小细胞肺癌和结肠直肠癌(CRC)肿瘤细胞系，EC50为0.021到 0.810 μM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7vTWM2OD1yLkCyPFA3KM7:TR?= NYf5Rog5W0GQR1XS
KS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfFTopKSzVyPUCuNFM5OzVizszN NIHITWVUSU6JRWK=
TE-11 M1LJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDIRY1vUUN3ME2wMlA4QDJ{IN88US=> NXjPPIp1W0GQR1XS
EW-1 NV\aS5pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PEbGlEPTB;MD6wPFU5PSEQvF2= NGHCSYVUSU6JRWK=
HMV-II NELr[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HLRWlEPTB;MD6wPFg1PiEQvF2= MorHV2FPT0WU
COLO-205 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37LcWlEPTB;MD6xNFQ2PCEQvF2= NUS4d4dkW0GQR1XS
ES1 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMUC2PVYh|ryP M3v1VnNCVkeHUh?=
GDM-1 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7jTWM2OD1yLkGzOlczKM7:TR?= M1fCOnNCVkeHUh?=
ML-2 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzCW3NqUUN3ME2wMlE2QDl4IN88US=> NEXPPZlUSU6JRWK=
Saos-2 M{DOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMU[1NlYh|ryP MWHTRW5ITVJ?
NCI-H1355 NXnDVWpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUew[YZlUUN3ME2wMlE5OTN3IN88US=> NVnBe41iW0GQR1XS
G-401 NWLQclRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPkTWM2OD1yLkG4NlMh|ryP NXTWZoZMW0GQR1XS
EW-16 NW\PSGhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLyXY5KSzVyPUCuNVg4PzdizszN M3vIU3NCVkeHUh?=
EW-7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7kT|ZKSzVyPUCuNVg5QDFizszN NYKxXmNVW0GQR1XS
NCI-H727 M1TmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMUm3PVQh|ryP M{fD[XNCVkeHUh?=
LCLC-97TM1 NYnJSFVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLTTWM2OD1yLkKwPVU2KM7:TR?= MWjTRW5ITVJ?
NCI-H650 NHjHbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMkGzPFQh|ryP Ml;6V2FPT0WU
NCI-H2122 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:yeIRKSzVyPUCuNlMzQTlizszN MUHTRW5ITVJ?
SK-N-DZ Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;XSW1KSzVyPUCuNlM3QThizszN M1jXNnNCVkeHUh?=
HT-29 NGTtVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDIdI0{UUN3ME2wMlI1OjR6IN88US=> M3;Hc3NCVkeHUh?=
LB771-HNC NVjUbohFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof6TWM2OD1yLkK1PVE2KM7:TR?= MVjTRW5ITVJ?
HT-144 NYjYNIZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3VWZMxUUN3ME2wMlI3OTlzIN88US=> NUXpO2J5W0GQR1XS
LAN-6 NFHMOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMk[zOFgh|ryP NFjTcIJUSU6JRWK=
EW-18 NELzXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[xTWM2OD1yLkK3NFAyKM7:TR?= M1XOXXNCVkeHUh?=
LS-1034 NYTId5diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMkexN|Ih|ryP Mn36V2FPT0WU
EW-11 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfKfVNKSzVyPUCuNlg1OzJizszN NGPO[|NUSU6JRWK=
SNU-C1 NVLKdGs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDFeFZKSzVyPUCuNlk{OTNizszN M4fFVnNCVkeHUh?=
RS4-11 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnftTWM2OD1yLkOzO|U5KM7:TR?= M1W4[HNCVkeHUh?=
ES4 NWXtZ2ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qySmlEPTB;MD60NVA{QCEQvF2= MUPTRW5ITVJ?
COLO-320-HSR M2\TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPaR|VGUUN3ME2wMlQyOzZ6IN88US=> MULTRW5ITVJ?
NB10 M3PXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP4TohKSzVyPUCuOFU1OzdizszN MmD6V2FPT0WU
BFTC-905 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwNE[3OVgh|ryP Ml\pV2FPT0WU
A375 NFLsO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\0O2lEPTB;MD60O|YyPyEQvF2= NHTNVYVUSU6JRWK=
SJRH30 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfqWXVVUUN3ME2wMlUxQDJ{IN88US=> M3HMeXNCVkeHUh?=
NOS-1 NUPaZXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\6cWlEPTB;MD61NlI3PyEQvF2= M1XIOHNCVkeHUh?=
SIG-M5 NF;Rc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;oTWM2OD1yLkWzOVU4KM7:TR?= MU\TRW5ITVJ?
DOK NHqyV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S1RWlEPTB;MD61OVYh|ryP Mk\vV2FPT0WU
NB69 NHPUSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwNUiyOVch|ryP M2LR[XNCVkeHUh?=
SK-NEP-1 NYfteWxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDGfm5EUUN3ME2wMlYxOjN4IN88US=> NUPXR2pKW0GQR1XS
SK-MM-2 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\O[lhKSzVyPUCuOlU1QTFizszN M2naU3NCVkeHUh?=
NCI-H358 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwNkewPFIh|ryP MojsV2FPT0WU
RH-1 NGDpSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjrdmRJUUN3ME2wMlc1QDV7IN88US=> MVnTRW5ITVJ?
NH-12 M1PlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLvTWM2OD1yLke2NFQ3KM7:TR?= MVXTRW5ITVJ?
TE-12 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T4TmlEPTB;MD63OlQ5PiEQvF2= M3vJcnNCVkeHUh?=
COLO-668 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTZTYZ5UUN3ME2wMlg1PjZ4IN88US=> M3zSbHNCVkeHUh?=
PANC-08-13 NXHn[oRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ftNWlEPTB;MD64OlM4PyEQvF2= Ml3JV2FPT0WU
HCC2998 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHuTWM2OD1yLki4NlY{KM7:TR?= NX;5[G1SW0GQR1XS
ABC-1 NVfiepFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXIXJZPUUN3ME2wMlkxOzV{IN88US=> MoX6V2FPT0WU
ES6 NEXFO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XRUmlEPTB;MD65NVA3PiEQvF2= MmjtV2FPT0WU
SNU-387 NH;5WoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwOUmzPVMh|ryP NHr1[JFUSU6JRWK=
CMK NVTxdpJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwOUm5Nlkh|ryP M3Hq[XNCVkeHUh?=
SJSA-1 M1\id2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XBV2lEPTB;MT6wN|Y2OyEQvF2= M1;RN3NCVkeHUh?=
SIMA M2H0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXkenJKSzVyPUGuNFY5OjVizszN MkTwV2FPT0WU
ES3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTtbllKSzVyPUGuNVIzQTdizszN MoDiV2FPT0WU
IGROV-1 NY\sTplNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi0TWM2OD1zLkG1OFQ1KM7:TR?= NFfE[G9USU6JRWK=
MEL-JUSO M3TOcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETsWHlKSzVyPUGuNVU4PTlizszN NH3RVpFUSU6JRWK=
T84 M17VPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;RU3FKSzVyPUGuNlA6OTRizszN MULTRW5ITVJ?
CAL-85-1 M1vnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHLcllKSzVyPUGuNlMyOzhizszN NVnTR2FlW0GQR1XS
RD NUK3UZNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwMk[0OVUh|ryP Mo\MV2FPT0WU
TE-8 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTFwM{G0OlIh|ryP MnLqV2FPT0WU
L-363 NELOO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXzRo9KSzVyPUGuN|QzODhizszN M{[zWXNCVkeHUh?=
EKVX MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwM{S1Olgh|ryP MoHsV2FPT0WU
SK-MEL-3 M2ezZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPRVZdKSzVyPUGuOFg2PTZizszN NITxWYhUSU6JRWK=
TGBC24TKB M{nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe4NWVMUUN3ME2xMlUxOTl|IN88US=> NUCyW2hoW0GQR1XS
NCI-H1770 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwNUGxNVMh|ryP MU\TRW5ITVJ?
HuH-7 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwNkCwPVgh|ryP MXPTRW5ITVJ?
HL-60 NIT2SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknqTWM2OD1zLk[2PVI5KM7:TR?= M{jOWXNCVkeHUh?=
TE-1 NWD1U5FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\yZ2lEPTB;MT63NFk1PSEQvF2= M4\qR3NCVkeHUh?=
LC-2-ad MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHTGlEPTB;MT63N|g5PyEQvF2= NIS0OW9USU6JRWK=
LB647-SCLC Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf0TWM2OD1zLke2OVg{KM7:TR?= NVXlRWdoW0GQR1XS
NCI-H2171 Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLHTWM2OD1zLke3O|E3KM7:TR?= MXvTRW5ITVJ?
SK-PN-DW MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfsWZRrUUN3ME2xMlkyOjl6IN88US=> Mn;jV2FPT0WU
MC-IXC NVraeIFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHve5pvUUN3ME2xMlk5QThizszN NFvVOY5USU6JRWK=
LS-513 M1LpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M133RmlEPTB;Mj6wOVMxPSEQvF2= MmPFV2FPT0WU
EW-3 NX2weHltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljNTWM2OD1{LkC5PFQ1KM7:TR?= MXnTRW5ITVJ?
OPM-2 MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILBZWtKSzVyPUKuNVAzKM7:TR?= NW[yeYxjW0GQR1XS
LP-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwMkW4NFch|ryP MXrTRW5ITVJ?
LU-134-A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnUS|dKSzVyPUKuNlc4KM7:TR?= NF\3RWdUSU6JRWK=
CP66-MEL M3WwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojmTWM2OD1{LkK5NFE1KM7:TR?= MWrTRW5ITVJ?
HCC1143 M2e4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjpWItKSzVyPUKuOFU{PjhizszN NIfYbIZUSU6JRWK=
LOXIMVI NUW4fVhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\3XWlEPTB;Mj62NFIyKM7:TR?= NX\GSIJ1W0GQR1XS
TE-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zqbmlEPTB;Mj63NFg{QCEQvF2= NYTLc5JPW0GQR1XS
NCI-H1882 M4T0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y0NGlEPTB;Mj63OVIzPyEQvF2= MWPTRW5ITVJ?
CHP-126 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknCTWM2OD1{Lke2N|E4KM7:TR?= MUPTRW5ITVJ?
NCI-H1623 M{n1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jNOWlEPTB;Mj65NlAzPCEQvF2= NYjWdGZJW0GQR1XS
GB-1 MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfnR|ZuUUN3ME2yMlk{PDB2IN88US=> NWixUnNsW0GQR1XS
RCC10RGB NV3PeY5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHvTWM2OD1{Lkm1NlgyKM7:TR?= M{n1bnNCVkeHUh?=
NCI-H2141 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTJTWM2OD1{Lkm2PFk3KM7:TR?= Mn\jV2FPT0WU
GI-ME-N NHLscpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHlbWFKSzVyPUOuNFA2PjVizszN MnnlV2FPT0WU
NCI-H526 Mmf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLobWxvUUN3ME2zMlA1ODh3IN88US=> MVLTRW5ITVJ?
NCI-H747 NIXZV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fzUmlEPTB;Mz6wOFk6OiEQvF2= NUHmbo9EW0GQR1XS
SNU-423 M4HIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPzTWM2OD1|LkKwN|E{KM7:TR?= NHy4SIlUSU6JRWK=
A427 M3O0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1d45KSzVyPUOuNlU3QTlizszN M4TnT3NCVkeHUh?=
CAL-12T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;p[29KSzVyPUOuOFA4OTNizszN MULTRW5ITVJ?
LU-99A MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;abGNKSzVyPUOuOFcyODVizszN MnPYV2FPT0WU
MS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GxSmlEPTB;Mz61N|QzQSEQvF2= MYjTRW5ITVJ?
SK-LU-1 NHK4XIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWZ4RVUUN3ME2zMlc3Ojl3IN88US=> NGrjclRUSU6JRWK=
SW837 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjPGlEPTB;Mz63OlM{OyEQvF2= NHXVdodUSU6JRWK=
ES8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLCcnNKSzVyPUOuPFM5PzdizszN NF\SZ5JUSU6JRWK=
MZ2-MEL NGX4VXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi1TWM2OD1|LkmyNFg3KM7:TR?= M{X6ZnNCVkeHUh?=
TGW MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32zWWlEPTB;ND6wNVMyOSEQvF2= MUHTRW5ITVJ?
GP5d NFnUc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hOWlEPTB;ND6wOVM3OiEQvF2= Mnq2V2FPT0WU
BB49-HNC M1PFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO5U3ZyUUN3ME20MlE2OjF|IN88US=> MlLiV2FPT0WU
NB13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q2RWlEPTB;ND6yOlg5PyEQvF2= NYHWeWtWW0GQR1XS
NTERA-S-cl-D1 NW\VbWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTLTWM2OD12LkK4OlE2KM7:TR?= MlXqV2FPT0WU
NCI-H1648 M2fB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTRwMkm4NVkh|ryP MnXLV2FPT0WU
LCLC-103H Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTRwM{KxPVUh|ryP Mn3oV2FPT0WU
LS-411N MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILNbpNKSzVyPUSuOFQ5QDVizszN NF3wUmtUSU6JRWK=
NCI-H1092 Ml;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPlXmpuUUN3ME20MlQ2Pjh5IN88US=> M1PGXnNCVkeHUh?=
PANC-10-05 M3vxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwNkm4OEDPxE1? MX;TRW5ITVJ?
DK-MG NVi5Xoo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrhTWM2OD12LkiwPVM{KM7:TR?= MknmV2FPT0WU
OVCAR-5 M3n1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3QTWM2OD12LkixNlI3KM7:TR?= MUTTRW5ITVJ?
CAL-39 NWDufIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe0Xmg2UUN3ME20Mlg4PjdizszN NG[4b4tUSU6JRWK=
TE-441-T M3LHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwOUC1N|ch|ryP MnzsV2FPT0WU
MOLT-16 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTKTWM2OD12Lkm1NlU{KM7:TR?= M1zF[HNCVkeHUh?=
MCF7 NYLVWXhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\3e2lEPTB;NT6xOFUyPyEQvF2= M4\ZNnNCVkeHUh?=
CAPAN-1 M2HEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPSNJB3UUN3ME21MlI2PzB5IN88US=> MlHWV2FPT0WU
PSN1 NGT4S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrcJRzUUN3ME21MlI4OjN3IN88US=> MYXTRW5ITVJ?
NCI-H292 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHPTWM2OD13LkOwNFQ1KM7:TR?= NWP6fYNyW0GQR1XS
CPC-N MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYOJhKSzVyPUWuN|k1OTlizszN NGXFN4lUSU6JRWK=
DoTc2-4510 M3;Z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPC[WpKSzVyPUWuOFU{PzFizszN MXHTRW5ITVJ?
LB1047-RCC M2LlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVwNUW5N|Mh|ryP NIDIZWhUSU6JRWK=
MHH-ES-1 MnfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwNUm5NFch|ryP M1;hVXNCVkeHUh?=
NMC-G1 NHr6c2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTVwN{CyNlch|ryP NGrVRXlUSU6JRWK=
SW1710 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwN{S3OVEh|ryP M1nKTXNCVkeHUh?=
YAPC NFHEWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DqZ2lEPTB;NT63OlIxOSEQvF2= NYnHUFNRW0GQR1XS
22RV1 M2[zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fFSmlEPTB;NT64NFAyQSEQvF2= MWnTRW5ITVJ?
COLO-679 NXj6epdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\oT4FKSzVyPUWuPFg6PDhizszN NFrjeZhUSU6JRWK=
TCCSUP MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTKV|dKUUN3ME21Mlk{OjV7IN88US=> NWToOZpDW0GQR1XS
C2BBe1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzKeZNoUUN3ME21Mlk{QTdizszN NYG0TYxyW0GQR1XS
TE-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[2[lV2UUN3ME22MlA3PjB3IN88US=> M4DWb3NCVkeHUh?=
SCLC-21H Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNeGlEPTB;Nj6xNFg1OyEQvF2= M1nyWHNCVkeHUh?=
EoL-1-cell MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjBTWM2OD14LkG2OVY{KM7:TR?= MWPTRW5ITVJ?
NKM-1 M2fvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PwbmlEPTB;Nj6xOlcyKM7:TR?= NYXIVpF1W0GQR1XS
NCI-H1304 M3PYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O1b2lEPTB;Nj6yO|QzQCEQvF2= MmHTV2FPT0WU
NB6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfUU5lKSzVyPU[uNlk3OjJizszN MlzoV2FPT0WU
NALM-6 M2fXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNeVVKSzVyPU[uN|MzOyEQvF2= M{DHZ3NCVkeHUh?=
NCI-H522 NVrxdW9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX0NJhKSzVyPU[uN|M{ODZizszN MWLTRW5ITVJ?
MV-4-11 NXu1[o1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13Pe2lEPTB;Nj6zO|A4QSEQvF2= M1;0eHNCVkeHUh?=
LB2241-RCC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDsTWM2OD14LkO4OlY4KM7:TR?= MoTpV2FPT0WU
NCI-H1417 NUXDZYhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZwNEC4OFch|ryP NITpRnpUSU6JRWK=
HT-1197 M333Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTBXVF[UUN3ME22MlU4OTJ{IN88US=> MVXTRW5ITVJ?
P30-OHK NV3sSG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\UOJFKSzVyPU[uOlI4PyEQvF2= NGfySW1USU6JRWK=
ALL-PO MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZwN{G5NVYh|ryP M3PHPXNCVkeHUh?=
OVCAR-4 NX7oc3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf1TopnUUN3ME22Mlc2PDB3IN88US=> NGSwS5hUSU6JRWK=
HCC2157 NILHT2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK0UGxnUUN3ME22Mlc4PDd3IN88US=> MWHTRW5ITVJ?
NCI-H838 M3G0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PtZWlEPTB;Nj65OlQ6KM7:TR?= NGS5SZJUSU6JRWK=
NCI-H1299 M3G2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHqSVBKSzVyPU[uPVcxQSEQvF2= M1GzVnNCVkeHUh?=
SW954 NHPrdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO3cGUxUUN3ME23MlIxODZ6IN88US=> MnHiV2FPT0WU
NCI-H441 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTdwM{SwOlUh|ryP NIHsXXVUSU6JRWK=
SK-MEL-2 NULkS5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[xO4N{UUN3ME23MlQ5Ozd|IN88US=> NH\BT3NUSU6JRWK=
KARPAS-45 NVrVPZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn5SlJwUUN3ME23MlY2QTJ7IN88US=> NGDqT2NUSU6JRWK=
CAL-54 NH3TNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH31O29KSzVyPUeuPFI6PzdizszN MofqV2FPT0WU
KYSE-180 M1q4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe2XXZSUUN3ME23Mlg5QTRzIN88US=> M{m3eHNCVkeHUh?=
NCI-H187 NGDUR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDGXJFKSzVyPUeuPVU6PDdizszN NXPqSWNLW0GQR1XS
RT-112 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL4TWM2OD16LkC5Olc4KM7:TR?= M2\hN3NCVkeHUh?=
NCI-H1437 M4GyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PtR2lEPTB;OD6wPVc6PSEQvF2= M1XoW3NCVkeHUh?=
SNU-449 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjGOYhKSzVyPUiuNlgzPzJizszN MnjzV2FPT0WU
HCC1187 NUPmUFRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S3fmlEPTB;OD6yPVM6OSEQvF2= MYrTRW5ITVJ?
NCI-H2030 MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTTTWM2OD16LkO3O|E1KM7:TR?= MXXTRW5ITVJ?
HuO-3N1 NXGyZlFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTLZlFKSzVyPUiuN|c5PDRizszN M4jmenNCVkeHUh?=
COLO-792 NYXBfnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X3dGlEPTB;OD60NVUzPyEQvF2= MmPNV2FPT0WU
MIA-PaCa-2 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XFfGlEPTB;OD64OVUxQCEQvF2= M3jncHNCVkeHUh?=
SK-N-FI MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP5[o8{UUN3ME25MlA1OjVizszN MXPTRW5ITVJ?
MMAC-SF NIez[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GwbmlEPTB;OT6wPVc2OSEQvF2= MUjTRW5ITVJ?
NCI-H28 M4Dic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTlwMUC0Olkh|ryP NGLwem9USU6JRWK=
ETK-1 NXq4Soc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTlwMkm5O|Qh|ryP NEe0e4ZUSU6JRWK=
NCI-H1993 NYOwZ2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTlwNESyOlEh|ryP MorPV2FPT0WU
no-11 NUT4WIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[1ZZhmUUN3ME25MlQ4OTJizszN NGSw[|ZUSU6JRWK=
ChaGo-K-1 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGyTWM2OD17LkWxOVg{KM7:TR?= NHnZ[4pUSU6JRWK=
NCCIT MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnkZmFKSzVyPUmuOVMyPjlizszN Mo[4V2FPT0WU
SAS NWraXY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nPTmlEPTB;MUCuNlQ5KM7:TR?= M{jaRnNCVkeHUh?=
A673 M4rS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;lfGlEPTB;MUCuN|cxPCEQvF2= MnrKV2FPT0WU
NCI-H1522 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\iTWM2OD1zMD6zO|A4KM7:TR?= NHLwSolUSU6JRWK=
NCI-H810 NHXsWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrjTWM2OD1zMD6zPVA4KM7:TR?= NH\YOVFUSU6JRWK=
IST-MES1 M1HBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFyLkS1OlQh|ryP Mn65V2FPT0WU
GR-ST NYKy[VdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTBUm5ZUUN3ME2xNE42ODJ2IN88US=> MVPTRW5ITVJ?
SUP-T1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFyLkezNVch|ryP NFyzOm9USU6JRWK=
NB5 NV;V[YhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHoTWM2OD1zMD65NFIzKM7:TR?= Mn;MV2FPT0WU
MZ1-PC NXjZSJdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4POVWlEPTB;MUCuPVU4OSEQvF2= NXzXXlRyW0GQR1XS
SK-CO-1 M3jFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLzTWM2OD1zMD65PVMyKM7:TR?= Mlf0V2FPT0WU
Capan-2 NHLO[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\NTWM2OD1zMT6zNVk5KM7:TR?= NX7GcnQ2W0GQR1XS
697 NWfXc2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHVTWM2OD1zMT62O|U4KM7:TR?= NWew[ZpmW0GQR1XS
REH M{DITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W3WWlEPTB;MUGuO|Q2OSEQvF2= MX\TRW5ITVJ?
GI-1 NHX6fphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7ITWM2OD1zMT64OlE2KM7:TR?= M2jLc3NCVkeHUh?=
BB65-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF{LkC5NVYh|ryP NIfqUXZUSU6JRWK=
NCI-H1651 NUHNSVc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n1V2lEPTB;MUKuNlQ4QCEQvF2= NFrFVmlUSU6JRWK=
NCI-H1618 NELZO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzHXm5KSzVyPUGyMlM6PzZizszN M2DmfHNCVkeHUh?=
NCI-H2081 NHjxeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDNdHdoUUN3ME2xNk43OTRzIN88US=> MVrTRW5ITVJ?
GCIY M3XDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXVNlNKSzVyPUGyMlczOTNizszN MX;TRW5ITVJ?
NY MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDofoc{UUN3ME2xN{4xPjR|IN88US=> MkGzV2FPT0WU
PANC-03-27 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPSO2pJUUN3ME2xN{4xQDB5IN88US=> NIHPb2VUSU6JRWK=
BHY NV75UJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf3TWM2OD1zMz6yNVIyKM7:TR?= NHrqVGtUSU6JRWK=
SK-OV-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrs[|dKSzVyPUGzMlM4PjNizszN MlzhV2FPT0WU
5637 NW\uclNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor4TWM2OD1zMz63O|U6KM7:TR?= M2DZT3NCVkeHUh?=
LC-1F MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLYNVVHUUN3ME2xOE4xOzV4IN88US=> NGHtOnhUSU6JRWK=
SNB75 NFrLN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fsN2lEPTB;MUSuNFM5OyEQvF2= MoP5V2FPT0WU
CHP-212 NVLSPW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLVOHE5UUN3ME2xOE4xPDZ2IN88US=> M2PRSHNCVkeHUh?=
HT-1376 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTF2LkGxNlYh|ryP NGPoRnJUSU6JRWK=
MONO-MAC-6 NHjzToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF2LkG1NFIh|ryP MUDTRW5ITVJ?
CA46 NFfTRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnZU2pPUUN3ME2xOE4yQDJ5IN88US=> NFzLfpVUSU6JRWK=
SCC-15 M2OzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF2LkW1PFMh|ryP M2jYeXNCVkeHUh?=
ATN-1 NYDOfHNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHxZ5NnUUN3ME2xOE43PjJ5IN88US=> M4K1THNCVkeHUh?=
NCI-H2405 M{\Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnvTWM2OD1zND64NVU4KM7:TR?= MmHOV2FPT0WU
NCI-H716 NXn1VHZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\kXVM5UUN3ME2xOE45PDl|IN88US=> MUnTRW5ITVJ?
SW620 NHjxNodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HmPGlEPTB;MUSuPVAyPCEQvF2= MU\TRW5ITVJ?
NCI-H226 NIHod|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OybGlEPTB;MUSuPVA5PSEQvF2= NFzifY1USU6JRWK=
SW962 NHfpZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXvOmJjUUN3ME2xOE46PDN{IN88US=> NIHKcYtUSU6JRWK=
KYSE-150 NEHjSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF2Lkm1OUDPxE1? NEnnN21USU6JRWK=
OCUB-M NWHy[YIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrtd|d7UUN3ME2xOE46QDh|IN88US=> MV;TRW5ITVJ?
ES7 M{LXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF3LkC5PFQh|ryP Mkf2V2FPT0WU
SW1463 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF3LkSyNlMh|ryP MVPTRW5ITVJ?
CAKI-1 NV7pWlQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rseGlEPTB;MUWuOVM1PiEQvF2= NYXLd4drW0GQR1XS
MKN28 NYfUbVdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyxTWM2OD1zNT61OFc6KM7:TR?= NGLDV|BUSU6JRWK=
SW13 M2PMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonWTWM2OD1zNT62NVgh|ryP Mk\SV2FPT0WU
A3-KAW M161W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfyNohKSzVyPUG1Mlk3QTdizszN M33pWHNCVkeHUh?=
LU-65 M2jWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WyR2lEPTB;MUWuPVc3QCEQvF2= NXjEbIdwW0GQR1XS
Calu-1 NUTNb2F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3GzPGlEPTB;MU[uNFM3QCEQvF2= NUWyZpBIW0GQR1XS
ST486 M2jFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF4LkC0N|Eh|ryP Mk\aV2FPT0WU
BB30-HNC NHzjNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TMPGlEPTB;MU[uNVI1PiEQvF2= MVPTRW5ITVJ?
EGI-1 NHfMWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\BTWM2OD1zNj60OFYh|ryP MUPTRW5ITVJ?
SH-4 NXrUdWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF4LkS3N|Eh|ryP NEXwTI5USU6JRWK=
MN-60 NE\EWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF5LkKyPVch|ryP M1jlfXNCVkeHUh?=
MPP-89 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTRdppKSzVyPUG3MlI1PTlizszN NFLxcohUSU6JRWK=
A2780 NUXoW5JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGyTGxRUUN3ME2xO{41OTN7IN88US=> NHWxdJJUSU6JRWK=
Daoy NIW1ToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[3ZpFKSzVyPUG3MlQ3QTVizszN MYLTRW5ITVJ?
NCI-H2126 NFWxPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr6UVRFUUN3ME2xO{41PzdzIN88US=> MmXUV2FPT0WU
NCI-H1563 M3XNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PDemlEPTB;MUeuOFkyPyEQvF2= M3LtWnNCVkeHUh?=
8-MG-BA NHuxPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLV[mVKSzVyPUG3MlY3PDhizszN MUDTRW5ITVJ?
786-0 M{G5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0WI9KSzVyPUG3Mlg{PTNizszN NHGyXGJUSU6JRWK=
AM-38 MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF5LkmzNFYh|ryP M1fISnNCVkeHUh?=
COLO-824 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPaXYRNUUN3ME2xPE41PDN4IN88US=> MoTjV2FPT0WU
SK-MEL-30 NXnlSIFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[wTWM2OD1zOD61NFgzKM7:TR?= NYLDV4VFW0GQR1XS
CESS NGTtUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGraZm1KSzVyPUG4Mlc3ODlizszN M2nR[XNCVkeHUh?=
BL-70 NIGzZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13UZ2lEPTB;MUiuPFE2PiEQvF2= M4TD[HNCVkeHUh?=
NCI-H2170 M1\4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPkTWM2OD1zOD65NVc6KM7:TR?= MmfvV2FPT0WU
HT-3 MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WzfmlEPTB;MUiuPVg{KM7:TR?= M{mwU3NCVkeHUh?=
BOKU MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfGTWM2OD1zOT6wN|gyKM7:TR?= M1vQSXNCVkeHUh?=
HPAF-II MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXjVo9QUUN3ME2xPU4{ODF3IN88US=> MXnTRW5ITVJ?
KGN MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTCTWM2OD1zOT60O|Y2KM7:TR?= MVzTRW5ITVJ?
MC-CAR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF7Lk[zNVMh|ryP NGX5WVFUSU6JRWK=
BHT-101 NGfSOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrmUVhpUUN3ME2xPU44PzdizszN M{PwOnNCVkeHUh?=
SW1783 NHGzNnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\1e2xKSzVyPUG5Mlc5ODZizszN MYrTRW5ITVJ?
KP-N-YN NHP3flRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPHTWM2OD1{MD6wNlYzKM7:TR?= NVvrOGVRW0GQR1XS
LU-165 NU\2bW9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrVT3lKSzVyPUKwMlU2PzFizszN NEHvWIRUSU6JRWK=
GOTO NIPTUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJyLk[0OVEh|ryP MXzTRW5ITVJ?
EFM-19 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrP[FN1UUN3ME2yNU4xPzF4IN88US=> M4GxVHNCVkeHUh?=
CTV-1 NWrEZYY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nWR2lEPTB;MkGuNVA2PCEQvF2= Mni1V2FPT0WU
HEL MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;aXoZKSzVyPUKxMlQzOTZizszN MkPhV2FPT0WU
SNU-C2B MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnw[21uUUN3ME2yNU41OjZizszN MWrTRW5ITVJ?
ECC4 NYDlUVl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWWJNKSzVyPUKxMlcxPyEQvF2= NW\WPHJlW0GQR1XS
NEC8 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJzLkizOlgh|ryP M2HsZnNCVkeHUh?=
KMOE-2 NWThfppCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjaNYVKSzVyPUKxMlg6OjFizszN M1v4WXNCVkeHUh?=
NCI-H524 NEPQZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ{LkC4NFgh|ryP MlyzV2FPT0WU
WSU-NHL NVXVN45ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPud2l4UUN3ME2yNk4yPTd5IN88US=> NEC4eldUSU6JRWK=
SF126 NHuyUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnocpBHUUN3ME2yNk4zPDZ7IN88US=> NGXYbpBUSU6JRWK=
HOP-92 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ{LkOxOlch|ryP NWq2cms5W0GQR1XS
CTB-1 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L3OWlEPTB;MkKuOFY4PyEQvF2= M1XMWXNCVkeHUh?=
KYSE-270 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D4bmlEPTB;MkKuPVM2PyEQvF2= NYHNc3JmW0GQR1XS
SK-MEL-24 M33hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHkZoVVUUN3ME2yN{4yQDdizszN NHjRUXpUSU6JRWK=
Calu-3 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jnfGlEPTB;MkOuNlEzQCEQvF2= M4H1NnNCVkeHUh?=
GAMG NYLSUpNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJ|LkKzOlch|ryP MYnTRW5ITVJ?
SW1573 NYqwcJlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\qeoRiUUN3ME2yN{44PDF3IN88US=> MoXrV2FPT0WU
MHH-NB-11 NUnKTo5GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrvc5RKSzVyPUK0MlAyQTRizszN NYjS[ms1W0GQR1XS
TK10 NYHaZopnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13Xc2lEPTB;MkSuOVAyOyEQvF2= NYLLWWw{W0GQR1XS
LB373-MEL-D NFTlVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfDTmJKSzVyPUK0MlYxPjRizszN NFPoXotUSU6JRWK=
KALS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXkfI9KSzVyPUK0Mlc{OjdizszN M{POdnNCVkeHUh?=
HUTU-80 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTzZ3pKSzVyPUK1MlgxOzJizszN MUjTRW5ITVJ?
HuP-T3 NXX1SWluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ4LkG2O|Qh|ryP NUnR[2U3W0GQR1XS
OE19 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqxWVYyUUN3ME2yOk4zOTV|IN88US=> MnT2V2FPT0WU
J82 M3PNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ4LkK0O|Eh|ryP NIrKT5NUSU6JRWK=
DU-4475 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW0c|ZKSzVyPUK2MlM5OTlizszN NVfG[GhiW0GQR1XS
DMS-53 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ4LkWxN|gh|ryP Mlm4V2FPT0WU
COLO-741 M{m5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ4LkizOFQh|ryP NFvGNFNUSU6JRWK=
SW48 NFHLV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfNTFlOUUN3ME2yOk45QDJizszN MXnTRW5ITVJ?
IGR-1 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILlWHZKSzVyPUK2Mlk{OzRizszN NUS4UWZUW0GQR1XS
639-V M1;iTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3jenR6UUN3ME2yO{4xOjR3IN88US=> NFzBXW5USU6JRWK=
LK-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPBTJhKSzVyPUK3MlQyPDFizszN M1fDXXNCVkeHUh?=
NCI-H2347 NEHISpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL3bXlKSzVyPUK3Mlk3QTlizszN Ml:5V2FPT0WU
NCI-H2228 NXTkfYpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPwXIJKSzVyPUK4MlA6ODVizszN NVPxUoVtW0GQR1XS
LS-123 NVvqdGFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHRbJluUUN3ME2yPE4yOjZ{IN88US=> MUPTRW5ITVJ?
U031 NUPwWJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jQcGlEPTB;MkiuNlUzKM7:TR?= NEjkdoFUSU6JRWK=
NCI-H1792 M3jI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGzcINCUUN3ME2yPE41PzJzIN88US=> NFL6enhUSU6JRWK=
NCI-H2087 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrYVY9KSzVyPUK4Mlc2PTJizszN MojWV2FPT0WU
NCI-H2342 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXYdFFKSzVyPUK5MlUzODhizszN NE\Uc3NUSU6JRWK=
SW626 NU\YXFlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH6NFdKSzVyPUK5Mlc2PiEQvF2= M33XN3NCVkeHUh?=
LB2518-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3NTWM2OD1{OT64NVUh|ryP NGDyT3RUSU6JRWK=
RXF393 NFfmOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH62cHhKSzVyPUOwMlA6PTJizszN NGXkdnFUSU6JRWK=
LC4-1 NVP5ZXJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILIOYJKSzVyPUOwMlMxQTJizszN MVvTRW5ITVJ?
NCI-H1694 M{LBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNyLk[2NlQh|ryP MYDTRW5ITVJ?
K5 NUfjfYs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;2cWRKSzVyPUOwMlk4ODJizszN NUfIdHZQW0GQR1XS
HDLM-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTNyLkm3NlUh|ryP NGjr[5NUSU6JRWK=
BCPAP MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIizTXFKSzVyPUOxMlg{PzlizszN M{fNcXNCVkeHUh?=
BC-3 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPUd3NKSzVyPUOyMlE1ODNizszN NHS3NXVUSU6JRWK=
LB996-RCC M1fTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN{LkKzOVgh|ryP MoLpV2FPT0WU
NCI-H2009 NHPVT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln4TWM2OD1|Mj60PVgyKM7:TR?= NX;sfpVTW0GQR1XS
HTC-C3 NIXSeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK3TWM2OD1|Mz63OVE6KM7:TR?= M2LpfnNCVkeHUh?=
LAMA-84 MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPvdXc5UUN3ME2zOE41PDB5IN88US=> NIDWTVRUSU6JRWK=
CCRF-CEM MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGmwe3pKSzVyPUO0MlU4OTVizszN M2\kenNCVkeHUh?=
AN3-CA NIDZT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[2TWM2OD1|NT6wOVY5KM7:TR?= Mmj1V2FPT0WU
NCI-H1734 M3m2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHOU3FKSzVyPUO1MlI2PjFizszN NGrSSY1USU6JRWK=
Ca-Ski MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKwUpZKSzVyPUO1MlQyODFizszN MXnTRW5ITVJ?
U-266 M{DjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTN3Lk[xNVQh|ryP MVnTRW5ITVJ?
SBC-5 NGiwUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOyfXFVUUN3ME2zOU44PzhzIN88US=> NFPHNlhUSU6JRWK=
GT3TKB NXvlNIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTN5LkGxOUDPxE1? MYXTRW5ITVJ?
MDA-MB-175-VII NHPIWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX0TWM2OD1|Nz6yNlQ5KM7:TR?= NGqzcJdUSU6JRWK=
PFSK-1 NX3MeG94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vCU2lEPTB;M{euNlQ{PSEQvF2= M{C5bHNCVkeHUh?=
IMR-5 M{TZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTrN5A{UUN3ME2zO{4zPDh5IN88US=> MUHTRW5ITVJ?
Daudi NGTNepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzXVJNKSzVyPUO3MlM2QTdizszN MXfTRW5ITVJ?
A498 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[0c2x[UUN3ME2zO{44OjF6IN88US=> M3GzSXNCVkeHUh?=
SCC-4 M2jacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2roRmlEPTB;M{euO|g1OyEQvF2= MV7TRW5ITVJ?
COLO-680N NGXweINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT4[2pKSzVyPUO4MlI5QDVizszN MkLlV2FPT0WU
SK-MES-1 NH\3blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PoUWlEPTB;M{iuN|IyPSEQvF2= NVfidodyW0GQR1XS
SR M4DuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG1bWFwUUN3ME2zPE42PDl3IN88US=> NFTpfXBUSU6JRWK=
LNCaP-Clone-FGC M1rWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\zTWM2OD1|OD61OlM4KM7:TR?= NHHSdpVUSU6JRWK=
SK-HEP-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYWwUJd{UUN3ME2zPE44QDJ{IN88US=> MXvTRW5ITVJ?
BPH-1 NU\yXGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFizZ3RKSzVyPUO4Mlg{OjlizszN M3PoRnNCVkeHUh?=
NCI-H1755 NYrNWph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjkTWM2OD1|OT61PFE4KM7:TR?= NYLIT3lFW0GQR1XS
LXF-289 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTodJJXUUN3ME2zPU45ODh2IN88US=> NWrPTHc2W0GQR1XS
SW1088 NEHxPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\NTYlKSzVyPUSwMlIyODdizszN NV\uTHA2W0GQR1XS
MOLT-4 M1nrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRyLkK5NFEh|ryP NFHneGpUSU6JRWK=
AsPC-1 NEXCUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HsPWlEPTB;NECuOFU5OyEQvF2= MnzZV2FPT0WU
HOP-62 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[0TWM2OD12MD62OVY5KM7:TR?= NIj0XINUSU6JRWK=
A172 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv4TWM2OD12MD64OVEyKM7:TR?= MVXTRW5ITVJ?
SN12C M1LjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DwTGlEPTB;NECuPVM5PSEQvF2= NIfHVIxUSU6JRWK=
MDA-MB-231 M1TWRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvlTWM2OD12MD65PFk5KM7:TR?= NELq[I1USU6JRWK=
RPMI-2650 NVvmZm1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T2V2lEPTB;NEGuNVU6OyEQvF2= NULqXoxXW0GQR1XS
KYSE-140 NVjlc4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\jPWRKSzVyPUSxMlgyOjNizszN Mnj2V2FPT0WU
KINGS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nMO2lEPTB;NEKuOFY6PyEQvF2= M33mO3NCVkeHUh?=
HSC-3 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR{Lk[2OlEh|ryP MonBV2FPT0WU
PC-14 NFHnT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXnOo5pUUN3ME20N{4yQDh{IN88US=> NHvrcpNUSU6JRWK=
COR-L105 NUSwWIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\PTWM2OD12Mz62OVAzKM7:TR?= MUPTRW5ITVJ?
BE-13 NHLEN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi1TWM2OD12ND6yN|cyKM7:TR?= MUHTRW5ITVJ?
NCI-H661 NXrPU|BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPQeJdKSzVyPUS0MlI6PThizszN NWnmS3pkW0GQR1XS
IST-MEL1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\oXIExUUN3ME20OE4{PTl7IN88US=> M{HXUHNCVkeHUh?=
HCC1806 NYD1[pc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETJepdKSzVyPUS0MlU5PzNizszN MnLYV2FPT0WU
COLO-800 M{fTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S5b2lEPTB;NESuPFQ2OyEQvF2= M1fk[XNCVkeHUh?=
IST-SL2 M1P6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR3LkGyOFch|ryP MoTMV2FPT0WU
8305C MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ThbGlEPTB;NEWuN|A6KM7:TR?= NWTTc3J{W0GQR1XS
UACC-62 MmDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX6TGtKSzVyPUS2MlI5PzVizszN MXnTRW5ITVJ?
COR-L23 M3PaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvzW4NKSzVyPUS3MlE6QSEQvF2= M3jkTHNCVkeHUh?=
EFE-184 NV;Qc2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTR5LkO4PEDPxE1? MWrTRW5ITVJ?
DMS-114 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLwTWM2OD12Nz60NVQ6KM7:TR?= NVy5VnhlW0GQR1XS
KYSE-520 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO0PYRKSzVyPUS4MlU{OTVizszN NU[3c|QzW0GQR1XS
SNG-M M3;sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR7LkSzOEDPxE1? MmTRV2FPT0WU
A2058 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknITWM2OD12OT60PFg2KM7:TR?= NXizO2J2W0GQR1XS

... Click to View More Cell Line Experimental Data
体内研究 OSI-906 作用于IGF-IR驱动的移植瘤鼠模型，抑制肿瘤生长，按 75 mg / kg剂量处理，导致100% TGI和 55% 衰退，按25 mg/kg剂量处理，导致 60% TGI，没有衰退。OSI-906处理犬，大鼠和小鼠，诱导不同的消除半衰期，消除半衰期分别为1.18 小时, 2.64小时 和2.14小时。OSI-906按不同剂量单独处理给药雌性Sprague-Dawley 大鼠和雌性CD-1小鼠，每天一次，Vmax值与OSI-906 剂量不成比例。OSI-906 按 25 mg/kg剂量处理12天，提高血糖值。OSI-906按75 mg/kg 剂量单独处理IGF-IR-驱动的人全长人类IGF-IR (LISN)移植鼠模型，在4 和24小时间最大程度抑制IGF-IR磷酸化(80%)，血浆药物浓度为26.6-4.77 μM。[1] OSI-906 按60 mg/kg剂量单独作用于NCI-H292 移植鼠，处理2，4，24小时，抑制糖吸收。OSI-906 作用于NCI-H292移植鼠模型，抑制肿瘤生长。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：[1]
+ 展开

蛋白激酶生化实验:

通过以ELISA为基础的检测法(IGF-IR, IR, EGFR 和 KDR)或使用100 µM ATP的放射检测法进行蛋白激酶检测实验。在内部ELISA检测实验中，使用聚 (Glu:Tyr)作为底物，结合到96孔实验板表面，使用辣根过氧化物酶标记的自磷酸化抗体测定磷酸化。使用ABTS作为过氧化物酶底物，通过在405/490 nm处测量吸光度而测定结合的抗体。所有实验使用纯化的重组激酶催化域。在昆虫细胞中，人类IGF-IR或EGFR的重组酶表达作为NH2-末端谷胱甘肽S-转移酶融合蛋白，且在内部纯化。通过抑制百分数对log10药品浓度的S型剂量-反应曲线测定IC50值。进行内部实验需重复进行实验，除非另有说明，取三次测量的最小值。
细胞实验：[1]
+ 展开
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 和Hepa-1, RKO 3T3/hulGF-IR, H292 细胞
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3天
  • Method: 为了测定细胞增殖，细胞接种在含FCS 10%的合适培养基上，在不同浓度OSI-906存在时，温育3天。通过细胞内ATP含量的荧光量化，使用CellTiterGlo测定抑制细胞生长的情况。数据作为衡量最大增殖的一部分，通过在不同浓度 OSI-906存在时的细胞密度除以对照组（只用DMSO处理）细胞密度。
    (Only for Reference)
动物实验：[1]
+ 展开
  • Animal Models: IGF-IR驱动的全长人类IGF-IR (LISN) 移植小鼠模型
  • Formulation: 25 mM 酒石酸
  • Dosages: 25 mg/kg和75 mg/kg
  • Administration: 口服处理，每天一次，持续14天
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
30% PEG 400+0.5% Tween 80+5% Propylene glycol 		30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.49
化学式

C26H23N5O
CAS号 867160-71-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答：

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

Selleck产品目录册

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

  • 泛IGF-1R抑制剂

    GSK1904529A : Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • 活性最高的IGF-1R抑制剂

    BMS-754807 : IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • 用于临床的IGF-1R抑制剂

    BMS-754807 : Phase II for Breast Cancer.

  • 最新的IGF-1R抑制剂

    PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

相关IGF-1R产品

  • Picropodophyllin (PPP) New

    Picropodophyllin (PPP)是一种选择性IGF-1R抑制剂，IC50为1 nM。它对IGF-IR具有高选择性，对IR的酪氨酸磷酸化或FGF-R、PDGF-R、EGF-R没有抑制作用。

  • Erlotinib New

    Erlotinib 是一种EGFR抑制剂，IC50 为 2 nM，对EGFR的敏感性比对人c-Src 或 v-Ab高1000多倍。

  • R428 (BGB324) New

    R428 (BGB324)是一种Axl抑制剂，IC50为14 nM，作用于Axl比作用于Abl选择性高100倍以上。作用于Axl选择性也比作用于Mer和Tyro3(高50到100倍)及InsR， EGFR， HER2，和PDGFRβ(高100倍以上)高。

  • BMS-536924

    BMS-536924是一种ATP竞争性的IGF-1R抑制剂，IC50为100 nM，对Mek， Fak，和Lck也具有适中的抑制活性，但对Akt1，和MAPK1/2几乎无抑制活性。

  • NVP-AEW541

    NVP-AEW541是一种有效的IGF-1R/InsR抑制剂，在无细胞试验中IC50为150 nM/140 nM，在细胞试验中对IGF-1R具有较高的作用和选择性。

  • NVP-ADW742

    NVP-ADW742是一种IGF-1R抑制剂，IC50为0.17 μM，作用于IGF-1R比作用于InsR效果强16倍以上；对HER2， PDGFR， VEGFR-2， Bcr-Abl和c-Kit几乎没有活性。

  • GSK1904529A

    GSK1904529A是一种选择性的IGF-1R和IR抑制剂，无细胞试验中IC50分别为27 nM和25 nM，作用于IGF-1R/InsR比作用于Akt1/2/， Aurora A/B，B-Raf， CDK2， EGFR等选择性高100倍以上。

  • BMS-754807

    BMS-754807是一种有效的IGF-1R/InsR可逆性抑制剂，在无细胞试验中IC50为1.8 nM/1.7 nM，对Met，Aurora A/B，TrkA/B和Ron作用稍弱，对Flt3， Lck，MK2，PKA，PKC等几乎没有抑制活性。Phase 2。

    Features:胰岛素样生长因子-1R/IR家族激酶的多重抑制剂

  • AG-1024

    AG-1024 抑制IGF-1R自磷酸化，IC50为7 μM，对IR作用效果稍弱，IC50为57 μM，且特异性区分InsR和IGF-1R（相比于其他酪氨酸磷酸化抑制剂）。

  • PQ 401

    PQ 401抑制IGF-1R区域自磷酸化，IC50为低于1 μM。

Tags: 购买Linsitinib (OSI-906) | Linsitinib (OSI-906)供应商 | 采购Linsitinib (OSI-906) | Linsitinib (OSI-906)价格 | Linsitinib (OSI-906)生产 | 订购Linsitinib (OSI-906) | Linsitinib (OSI-906)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID